FindTrial
Sign In

Effect of Menaquinone supplementation on insulin resistance, lipid profile, anthropometric measurments, endocrine markers and oxidative stress in patients with polycystic ovary syndrome who will be referred to health centers of Shiraz University of Medical Sciences, 1396.

Effect of Menaquinone supplementation on insulin resistance, lipid profile, anthropometric measurments, endocrine markers and oxidative stress in patients with polycystic ovary syndrome who will be referred to health centers of Shiraz University of Medical Sciences, 1396.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017092836204N2
Enrollment
84
Registered
2017-10-25
Start date
2017-06-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome. polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: 1 capsule containing 90 micrograms of menaquinone per day for 8 weeks. Intervention 2: Control group: 1 placebo capsule containing avesil per day for 8 weeks.
Treatment - Drugs
Placebo
Intervention group: 1 capsule containing 90 micrograms of menaquinone per day for 8 weeks
Control group: 1 placebo capsule containing avesil per day for 8 weeks

Sponsors

Vice chancellor for research, Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Suffering from polycystic ovary syndrome based on Rotterdam criteria; age between 18 to 40 ; absecnce of pregnancy or lactation; absence of antidiabetic, antihypertensive, antihyperlipidemic, anticoagulant treatment; absence of using metformin 2 months before entering the study and during the intervention; acute or chronic inflammation; absence of any current diet or supplement treatment; absence of antidiabetic, antihypertensive, antihyperlipidemic treatment; absence of using drugs effective on bone metabolism; any disease or physiological changes that requires special treatment; nonsmoker, nonalcoholic. Exclusion criteria: Unwillingness to continue; any disease or physiological changes that requires special treatment; failure to follow the intervention designing (not consuming dedicated supplement to the total amount less than 90% predicted or more than 3 days).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Fasting blood sugar. Timepoint: Before and after intervention. Method of measurement: auto analyser.;Dehydroepiandrosterone Sulfate (DHEAS). Timepoint: Before and after intervention. Method of measurement: ELISA kit.—

Secondary

MeasureTime frame
Total testosterone. Timepoint: Before and after intervention. Method of measurement: ELISA kit.;Malondialdehyde (MDA). Timepoint: Befor and after intervention. Method of measurement: Spectrophotometry.;Dihydrotestosterone (DHT). Timepoint: Before and after intervention. Method of measurement: ELISA kit.;Sex Hormone Binding Globulin (SHBG). Timepoint: Before and after intervention. Method of measurement: ELISA kit.;Lipid profile (TG, Cholesterol, HDL, LDL). Timepoint: Before and after intervention. Method of measurement: auto analyser.;Fasting insulin. Timepoint: Before and after intervention. Method of measurement: ELISA kit.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFiroozeh Tarkesh

Shiraz University of Medical Sciences, Faculty of Nutrition and Food Sciences

firoozeh_tarkesh@yahoo.com+98 71 3725 1001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026